votrient
(pazopanib hydrochloride)Novartis Pharmaceuticals Corporation
Usage: VOTRIENT® is indicated for treating adults with advanced renal cell carcinoma and advanced soft tissue sarcoma in those who have previously undergone chemotherapy. Its efficacy has not been established for adipocytic soft tissue sarcomas or gastrointestinal stromal tumors.